echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > J Urol: Can blue light cystoscopy improve the detection rate of recurrence in patients with non-muscular invasive bladder cancer?

    J Urol: Can blue light cystoscopy improve the detection rate of recurrence in patients with non-muscular invasive bladder cancer?

    • Last Update: 2021-12-03
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Some studies and recent meta-analysis have shown that compared with white light cystoscopy (WLC), blue light cystoscopy (BLC) is associated with an increase in the detection rate of primary tumors and tumor recurrence, a decrease in recurrence rate and a longer time to first recurrence Related
    .
    Therefore, the current guidelines of the American Urological Association recommend that clinicians perform blue-light cystoscopy when performing transurethral resections (TURBTs) for patients with non-muscular invasive bladder cancer (NMIBC)

    .
    Although the previous consensus statement provided expert advice, there is no guideline for incorporating blue light cystoscopy into the NMIBC patient monitoring program, so the use of blue light cystoscopy for monitoring is still at the discretion of the doctor
    .

    Although the previous consensus statement provided expert advice, there was no guideline for incorporating blue light cystoscopy into the NMIBC patient monitoring program.
    Therefore, the use of blue light cystoscopy for monitoring is still at the discretion of the doctor.
    Although the previous consensus statement provided expert advice, no guidance on the blue light cystoscopy in patients with NMIBC into the monitoring program, so using blue light cystoscopy to monitor individual doctors still decided to consensus

    After BCG (BCG) treatment, the utility of blue light cystoscopy (BLC) in cystoscopy is not very clear
    .
    Recently, researchers from the United States published an article in "J Urol" magazine to
    determine whether BLC can improve the detection rate of recurrence in patients receiving BCG treatment of non-muscle invasive bladder cancer (NMIBC)
    .

    Determined whether BLC can increase the detection rate of recurrence in patients receiving BCG in non-muscle invasive bladder cancer (NMIBC)

    The researchers used prospective multi-agency Cysview registry data (2014-2019) to include NMIBC patients who received BCG treatment within the first year of BLC
    .
    The main result is the recurrence and whether the lesion can be detected by white light cystoscopy (WLC), BLC, or both cystoscopy

    .
    The researchers calculated the percentage of recurrences missed by WLC but detected by BLC

    .
    The false positive rate of BLC at the cystoscopy level refers to the proportion of cystoscopy that undergoes biopsy only because of suspicious BLC lesions, but the real situation is that there is no recurrence

    .

    A total of 1703 cases of BLC were included in the study, and 282 cases of cystoscopy eventually entered the analysis cohort
    .
    The results showed that the total recurrence detection rate of 282 cases of cystoscopy was 45.
    0% (n=127)

    .
    If only WLC is performed, 13% (n=16/127) of the recurrence will be missed, and 5.
    7% (n=16/282) of the cystoscopy will only be determined by BLC

    .
    Among the 16 relapsed patients missed by WLC, 88% (n=14) had CIS

    .
    The false positive rate of BLC at the cystoscope level was 5% (n=15)

    .

    Indications and intervals of 16 patients with recurrence detected by BLC

    Indications and intervals of 16 patients with recurrence detected by BLC

    To sum up, BLC helps to detect recurrence after recent BCG treatment, while WLC alone will lead to missed diagnosis
    .
    Therefore, doctors should consider performing BLC for high-risk patients receiving BCG and discuss the risk of false positives with these patients

    .
    In addition, with the increase in clinical trials of new therapies for BCG non-responsive diseases, and there are no clear guidelines on whether to use BLC in cystoscopy after treatment, it is important to consider how the use of BLC affects the recruitment and comparison of these studies

    .

    BLC helps to detect recurrence after recent BCG treatment, but missed diagnosis occurs only with WLC BLC helps to detect recurrence after recent BCG treatment, but missed diagnosis occurs only with WLC

    Original source:

    Original source:

    Meera R Chappidi, Heiko Yang, Maxwell V Meng et al.
    Utility of Blue Light Cystoscopy for Post-BCG Bladder Cancer Recurrence Detection: Implications for Clinical Trial Recruitment and Study Comparisons .
    J Urol.
    Oct 2021

    Utility of Blue Light Cystoscopy for Post-BCG Bladder Cancer Recurrence Detection: Implications for Clinical Trial Recruitment and Study Comparisons

     



    Leave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.